Table SII. Summary of sites of mucocutaneous lesions in 332 patients with BP180-mucous membrane pemphigoid (MMP)

<table>
<thead>
<tr>
<th>Category</th>
<th>Patients, n</th>
<th>Restricted to the sites, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucous lesions</td>
<td>332</td>
<td>200</td>
</tr>
<tr>
<td>Oral</td>
<td>284</td>
<td>106</td>
</tr>
<tr>
<td>Lips</td>
<td>33</td>
<td>0</td>
</tr>
<tr>
<td>Gingival</td>
<td>93</td>
<td>26</td>
</tr>
<tr>
<td>Buccal</td>
<td>60</td>
<td>5</td>
</tr>
<tr>
<td>Palate</td>
<td>60</td>
<td>1</td>
</tr>
<tr>
<td>Tongue</td>
<td>23</td>
<td>0</td>
</tr>
<tr>
<td>Ocular</td>
<td>97</td>
<td>16</td>
</tr>
<tr>
<td>Nasal</td>
<td>11</td>
<td>0</td>
</tr>
<tr>
<td>Laryngeal</td>
<td>35</td>
<td>2</td>
</tr>
<tr>
<td>Pharyngeal</td>
<td>42</td>
<td>1</td>
</tr>
<tr>
<td>Oesophageal</td>
<td>14</td>
<td>0</td>
</tr>
<tr>
<td>Genital</td>
<td>32</td>
<td>2</td>
</tr>
<tr>
<td>Others</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Skin lesions</td>
<td>132</td>
<td>0</td>
</tr>
<tr>
<td>Trunk</td>
<td>98</td>
<td>0</td>
</tr>
<tr>
<td>Extremities</td>
<td>94</td>
<td>0</td>
</tr>
</tbody>
</table>